Einzeltreffer — DigiBib

Background/aim: The pathogenesis of cardio-vascular disease (CVD) in hemodialysis (HD) patients involves inflammation and oxidative stress. High-sensitivity C-reactive protein (hs-CRP) is an established inflammatory biomarker associated with CVD. Several studies have suggested that the inflammatory biomarker pentraxin-3 (PTX-3) and the oxidative stress-related biomarker soluble lectin-like low-density lipoprotein receptor-1 (sLOX-1) are novel biomarkers for CVD in non-HD populations. This study aimed to clarify the association of these established and novel biomarkers with future cardiovascular (CV) events in HD patients.

Patients and Methods: This was a single-center prospective cohort study that included 255 HD patients. The primary outcome was the composite of nonfatal and fatal CV events. The event-free survival rate between the two groups according to the median plasma level of each biomarker at baseline was evaluated using the Kaplan-Meier method. The risk for CV events at elevated levels of each biomarker was estimated using Cox proportional hazard model.

Results: We observed 44 CV events during the median follow-up period of 743 days. The event-free survival rate significantly differed between the two groups in hs-CRP but not in PTX-3 or sLOX-1. The unadjusted hazard ratio (HR) for CV events in patients with hs-CRP levels above the median was 2.63 [95% confidence interval (CI)=1.37-5.02]. The HR remained significant after adjusting for age, sex, history of CVD, and diabetes (HR=2.30; 95%CI=1.20-4.43).

Conclusion: In HD patients, hs-CRP may have a predictable role for future CV events, whereas PTX-3 and sLOX-1 do not.

Titel:	Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients.
Autor/in / Beteiligte Person:	Osawa, H ; Nakamura, N ; Tsutaya, C ; Saitoh, H ; Shimada, M ; Murakami, R ; Fujita, T ; Narita-Kinjo, I ; Nagawa, D ; Nakata, M ; Yokota, T ; Ohyama, C ; Tomita, H
Zeitschrift:	In vivo (Athens, Greece), Jg. 38 (2024-05-01), Heft 3, S. 1351-1358
Veröffentlichung:	<2000- > : Attiki, Greece : International Institute of Anticancer Research ; <i>Original Publication</i>: Athens : Dr. J.G. Delinassios, 2024
Medientyp:	academicJournal
ISSN:	1791-7549 (electronic)
DOI:	10.21873/invivo.13575
Schlagwort:	Humans Male Female Middle Aged Aged Prospective Studies Serum Amyloid P-Component metabolism Risk Factors Proportional Hazards Models Kaplan-Meier Estimate Prognosis C-Reactive Protein metabolism Renal Dialysis Cardiovascular Diseases etiology Cardiovascular Diseases blood Biomarkers blood
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [In Vivo] 2024 May-Jun; Vol. 38 (3), pp. 1351-1358. MeSH Terms: C-Reactive Protein* / metabolism ; Renal Dialysis* ; Cardiovascular Diseases* / etiology ; Cardiovascular Diseases* / blood ; Biomarkers* / blood ; Humans ; Male ; Female ; Middle Aged ; Aged ; Prospective Studies ; Serum Amyloid P-Component / metabolism ; Risk Factors ; Proportional Hazards Models ; Kaplan-Meier Estimate ; Prognosis References: Acta Cardiol. 2016 Apr;71(2):185-90. (PMID: 27090040) ; Atherosclerosis. 2017 Apr;259:75-82. (PMID: 28327451) ; J Atheroscler Thromb. 2017 Jun 1;24(6):572-582. (PMID: 27840386) ; Int J Vasc Med. 2016;2016:6015701. (PMID: 27559483) ; Int J Nephrol. 2014;2014:297954. (PMID: 25587447) ; Int J Cardiol. 2013 Oct 9;168(4):3217-23. (PMID: 23632121) ; Circ J. 2014;78(1):159-69. (PMID: 24132243) ; Blood Purif. 2000;18(1):30-6. (PMID: 10686440) ; J Atheroscler Thromb. 2010 Apr 30;17(4):317-31. (PMID: 20009416) ; QJM. 2008 May;101(5):397-405. (PMID: 18292098) ; Vascul Pharmacol. 2006 Nov;45(5):326-30. (PMID: 17023219) ; Clin Chem. 2004 Dec;50(12):2279-85. (PMID: 15364888) ; Circulation. 2009 Aug 25;120(8):699-708. (PMID: 19667236) ; Atherosclerosis. 2009 May;204(1):234-8. (PMID: 18790479) ; J Thromb Haemost. 2014 Jun;12(6):999-1005. (PMID: 24628740) ; Clin Chem. 2010 Apr;56(4):550-8. (PMID: 20093560) ; Clin Chim Acta. 2015 Feb 2;440:157-63. (PMID: 25463747) ; Int J Vasc Med. 2012;2012:657025. (PMID: 22347626) ; Ther Apher Dial. 2011 Feb;15(1):44-50. (PMID: 21272252) ; Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1385-91. (PMID: 18403728) ; In Vivo. 2023 May-Jun;37(3):1182-1185. (PMID: 37103116) ; Scand J Urol Nephrol. 2004;38(5):405-16. (PMID: 15764253) ; Eur J Immunol. 2003 Feb;33(2):465-73. (PMID: 12645945) ; Am J Kidney Dis. 2000 Mar;35(3):469-76. (PMID: 10692273) ; Am Heart J. 2008 Jan;155(1):75-81. (PMID: 18082493) ; Int J Cardiol. 2009 May 15;134(2):285-7. (PMID: 18367271) ; Circ J. 2010 Jul;74(7):1399-404. (PMID: 20467154) ; Nephrol Dial Transplant. 2018 Jan 1;33(1):102-112. (PMID: 27798199) ; Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):e10-4. (PMID: 12006411) ; Kidney Int. 2004 Jun;65(6):2380-9. (PMID: 15149351) ; Atherosclerosis. 2012 Feb;220(2):581-6. (PMID: 22178425) ; Can Respir J. 2022 Apr 11;2022:6619331. (PMID: 35449557) ; Curr Med Chem. 2015;22(22):2680-9. (PMID: 25891107) ; Pol Arch Intern Med. 2017 Feb 27;127(3):170-177. (PMID: 28377558) ; Kidney Blood Press Res. 2005;28(1):55-61. (PMID: 15550763) ; Metabolism. 2013 Jul;62(7):935-8. (PMID: 23433938) ; Nephrol Dial Transplant. 2007 Aug;22(8):2224-9. (PMID: 17496115) ; Ther Apher Dial. 2018 Apr;22(2):109-117. (PMID: 29205940) Contributed Indexing: Keywords: High-sensitivity C-reactive protein; cardiovascular events; hemodialysis; pentraxin-3; soluble lectin-like low-density lipoprotein receptor-1 Substance Nomenclature: 9007-41-4 (C-Reactive Protein) ; 0 (Biomarkers) ; 148591-49-5 (PTX3 protein) ; 0 (Serum Amyloid P-Component) Entry Date(s): Date Created: 20240430 Date Completed: 20240430 Latest Revision: 20240504 Update Code: 20240504 PubMed Central ID: PMC11059910

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients.